Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Purchases $526,121.52 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan purchased 261,752 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were purchased at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the transaction, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Raju Mohan also recently made the following trade(s):

• On Friday, November 22nd, Raju Mohan acquired 238,248 shares of Ventyx Biosciences stock. The stock was acquired at an average cost of $1.83 per share, with a total value of $435,993.84.

Ventyx Biosciences Stock Performance

Shares of NASDAQ VTYX opened at $2.65 on Thursday. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The company has a market cap of $187.38 million, a PE ratio of -1.12 and a beta of 0.37. The business has a 50-day simple moving average of $2.19 and a two-hundred day simple moving average of $2.62.

Institutional Trading of Ventyx Biosciences

Several large investors have recently bought and sold shares of the stock. Palumbo Wealth Management LLC purchased a new stake in shares of Ventyx Biosciences during the third quarter valued at $26,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Ventyx Biosciences during the second quarter worth about $32,000. Intech Investment Management LLC purchased a new stake in Ventyx Biosciences in the third quarter valued at approximately $42,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after buying an additional 7,096 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Wall Street Analyst Weigh In

VTYX has been the subject of several research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. Canaccord Genuity Group dropped their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. Finally, Wells Fargo & Company cut their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.